[go: up one dir, main page]

AR007530A1 - Gel para la administracion transdermica - Google Patents

Gel para la administracion transdermica

Info

Publication number
AR007530A1
AR007530A1 ARP970102497A ARP970102497A AR007530A1 AR 007530 A1 AR007530 A1 AR 007530A1 AR P970102497 A ARP970102497 A AR P970102497A AR P970102497 A ARP970102497 A AR P970102497A AR 007530 A1 AR007530 A1 AR 007530A1
Authority
AR
Argentina
Prior art keywords
agent
gel
combination
glycol
transdermic administration
Prior art date
Application number
ARP970102497A
Other languages
English (en)
Original Assignee
Permatec N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Permatec N V filed Critical Permatec N V
Publication of AR007530A1 publication Critical patent/AR007530A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmaceútica en forma de gel apropiada para la administración transdermica de un agente activo de la clase de estrógenos yprogestina o de una mezcla de ambos, compuesta por: a) un intensificador de permeabilidad delo s agentes acitvos previamente mencionados, una combinacióncompuesta fundamentalmente por un alcohol alifático cuya fórmula general es CH3 (CH2)n CH2OH, en la cual n = 8-16 y por un éter monoalquil de glicoldietileno; b) un excipiente o agentecat alizador, una combinación de un alkanol de 2+4 C átomos, un glicol y agua; c) una amina terciaria como agenteespesante y neutralizante.
ARP970102497A 1996-06-06 1997-06-06 Gel para la administracion transdermica AR007530A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI001152A IT1283102B1 (it) 1996-06-06 1996-06-06 Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele

Publications (1)

Publication Number Publication Date
AR007530A1 true AR007530A1 (es) 1999-11-10

Family

ID=11374388

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102497A AR007530A1 (es) 1996-06-06 1997-06-06 Gel para la administracion transdermica

Country Status (14)

Country Link
US (1) US5891462A (es)
EP (1) EP0811381B1 (es)
JP (1) JP4293293B2 (es)
AR (1) AR007530A1 (es)
AT (1) ATE238801T1 (es)
AU (1) AU712465B2 (es)
CA (1) CA2207144C (es)
DE (1) DE69721377T2 (es)
DK (1) DK0811381T3 (es)
ES (1) ES2198516T3 (es)
IT (1) IT1283102B1 (es)
NZ (1) NZ328021A (es)
TW (1) TW565462B (es)
ZA (1) ZA974981B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
ES2318233T3 (es) 1997-11-10 2009-05-01 Strakan International Limited Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona.
JP3987655B2 (ja) * 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有した経皮適用製剤又は坐剤
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
AU769315B2 (en) 1999-08-24 2004-01-22 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CA2406064C (en) * 2000-04-26 2011-03-15 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
DE10025970C2 (de) * 2000-05-25 2002-04-25 Lohmann Therapie Syst Lts Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
DE60143360D1 (de) 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
US7572780B2 (en) * 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20040253326A1 (en) * 2003-02-25 2004-12-16 Mesko Charles A. Composition for increasing levels of hormones and a method for preparation of said composition
CN1997357A (zh) * 2003-03-11 2007-07-11 安塔雷斯制药Ipl股份公司 透皮或透粘膜应用活性剂的用途和制剂
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
JO2492B1 (en) 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US7879357B2 (en) 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
JP4969050B2 (ja) * 2005-01-07 2012-07-04 ロート製薬株式会社 皮膚外用剤
JP2007045808A (ja) * 2005-01-07 2007-02-22 Rohto Pharmaceut Co Ltd 皮膚外用剤
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
FI3456329T3 (fi) 2005-10-12 2025-02-27 Besins Healthcare Lu Sarl Parannettu testosteronigeeli ja käyttömenetelmä
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US8507467B2 (en) 2007-09-20 2013-08-13 Shiseido Company, Ltd. Transdermally absorbable preparation
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
FR2954980B1 (fr) 2010-01-04 2012-02-10 Guillemot Corp Joystick a ressorts de compensation, procede de fabrication et manette correspondants.
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
JP5820206B2 (ja) * 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
JP5820207B2 (ja) 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) * 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10264664B1 (en) 2015-06-04 2019-04-16 Vlt, Inc. Method of electrically interconnecting circuit assemblies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10556717B2 (en) 2017-03-10 2020-02-11 E-Pac Packaging Services Co. Ltd. Packaging assembly comprising a tightening portion, a box portion, a flexible strip and a pair of securing members
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN117545474A (zh) 2021-11-08 2024-02-09 李维庸 一种用于向患者递送药物的透皮给药系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4942158A (en) * 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
ATE132751T1 (de) * 1988-10-27 1996-01-15 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
JP3046346B2 (ja) * 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process

Also Published As

Publication number Publication date
ITMI961152A1 (it) 1997-12-06
ITMI961152A0 (it) 1996-06-06
ZA974981B (en) 1998-01-23
DE69721377T2 (de) 2004-04-01
ATE238801T1 (de) 2003-05-15
US5891462A (en) 1999-04-06
EP0811381A1 (en) 1997-12-10
DE69721377D1 (de) 2003-06-05
ES2198516T3 (es) 2004-02-01
AU2472997A (en) 1997-12-11
TW565462B (en) 2003-12-11
EP0811381B1 (en) 2003-05-02
JP4293293B2 (ja) 2009-07-08
IT1283102B1 (it) 1998-04-07
NZ328021A (en) 1997-11-24
CA2207144C (en) 2008-07-29
AU712465B2 (en) 1999-11-04
JPH1072351A (ja) 1998-03-17
DK0811381T3 (da) 2003-08-25
CA2207144A1 (en) 1997-12-06

Similar Documents

Publication Publication Date Title
AR007530A1 (es) Gel para la administracion transdermica
MX9702699A (es) Composiciones farmaceuticas.
ES2106029T3 (es) Composiciones que mejoran la penetracion a traves de la piel.
AR006050A1 (es) Composicion limpiadora y astringente para dejar sobre la piel, procedimiento para prepararla y metodo para limpiar la piel que la utiliza.
MX9308012A (es) Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
CO5021207A1 (es) Composiciones surfactantes agroquimicas que contienen agroquimicos de fase dispersada y alcoxilatos de alcohol primario ramificado como adyuvantes y metodo de aplicacion
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
MX9305146A (es) Conjugado de interferon, procedimiento para su preracion y composicion farmaceutica que lo contienen.
BR9917089A (pt) Composições e métodos para distribuição mucosal
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
DE3381396D1 (de) Formulierung nicht irritierender ophthalmischer waesseriger zusammensetzungen fuer okular-therapeutische mittel.
ES2101330T3 (es) Composicion farmaceutica para uso topico que contiene un polimero cationico reticulado y un eter alcoxilado.
DE60133555D1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
AU560864B2 (en) Pharmaceutical parenteral compositions of an avermectin and propylene glycol
ES2122220T3 (es) Agente para la limpieza de superficies duras.
ES2169536T3 (es) Agente de limpieza pobre en espuma.
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
ES2039377T3 (es) Un supositorio.
ES2150404T1 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ATE223221T1 (de) Lösliche arzneizusammensetzungen enthaltend 2- chloro-2'-deoxyadenosine
SE0302924D0 (sv) Pharmaceutical composition having a cationic excipient
MX9207344A (es) Formulaciones mejoradas que tienen mejoradores hidrofobicos de penetracion transdermica y metodo para proveerla.
JPS5443212A (en) Shampoo composition

Legal Events

Date Code Title Description
FG Grant, registration